Clinical Trial Update: Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating sintilimab plus lenvatinib versus HAIC as perioperative therapy for resectable hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• HAIC (hepatic artery infusion chemotherapy)
• Lenvatinib (lenvatinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Resectable Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN